)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (AUPH) investor relations material
Aurinia Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Q3 revenue rose 14% YoY to $83.7 million; nine-month revenue increased 19% to $244.6 million, and nine-month net income reached $103.5 million.
Cash, cash equivalents, restricted cash and investments totaled $486.9 million at September 30, 2026; nine-month operating cash flow was $131.5 million.
2026 revenue guidance increased to $325M–$330M, while development advanced for PRESERVE and aritinercept.
Financial highlights
Q3 net income was $31.7 million, flat YoY; nine-month net income was $103.5 million versus $76.4 million.
Q3 operating income was $35.4 million versus $29.7 million; nine-month operating income was $123.1 million versus $71.7 million.
Q3 SG&A declined to $24.7 million from $26.2 million YoY; R&D increased to $16.6 million from $8.4 million.
Outlook and guidance
2026 total revenue guidance rose from $315M–$325M to $325M–$330M; net product sales guidance narrowed from $305M–$315M to $310M–$315M.
SG&A expense is expected to remain substantially consistent, while R&D expense is expected to increase as development progresses.
Existing cash and operating cash flows are expected to fund operations under current plans; additional equity or debt financing may be pursued if needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aurinia Pharmaceuticals
- Strong revenue and profit growth driven by LUPKYNIS and robust 2026 outlook.AUPH
Q2 2026 - Revenue up 24% to $77.7M, net income $34.4M, and new executive team appointed.AUPHQ1 2026
- Shareholders will vote on directors, auditor, and executive pay, with strong governance and oversight.AUPHProxy filing
- LUPKYNIS sales and net income surged in 2025, with strong growth and robust 2026 guidance.AUPHQ4 2025
- Strong financials, global growth, and pipeline progress drive optimism for the year.AUPH2024 Cantor Fitzgerald Global Healthcare Conference
- Q3 2024 net income rose to $14.4M as restructuring and LUPKYNIS growth drove record results.AUPHQ3 2024
- Q2 revenue up 38% year-over-year, net income positive, and 2024 guidance narrowed to $210–$220M.AUPHQ2 2024
- LUPKYNIS posts strong growth, with global expansion and pipeline progress fueling future prospects.AUPHJefferies 2024 Global Healthcare Conference
- Record Lupkynis sales and return to profitability in 2024 support continued growth in 2025.AUPHQ4 2024
Next Aurinia Pharmaceuticals earnings date
Q4 202625 Feb, 2027
Aurinia Pharmaceuticals
Next Aurinia Pharmaceuticals earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aurinia is a biopharmaceutical company driven by a relentless commitment to bring life-changing therapies, like voclosporin, to patients suffering from diseases with high unmet medical need. The Company’s lead product, voclosporin, is being investigated as a therapy for LN. The Company is initially targeting LN and has plans to study additional disease indications. The company is headquartered in Victoria, Canada.